title: Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
abstract: The optimal choice of salvage therapy for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma (HL) remains unknown. Based on promising results of phase II trials, the preferred salvage regimen in British Columbia since 2002 has been the out-patient regimen, gemcitabine, dexamethasone, and cisplatin (GDP). We conducted a retrospective analysis including all patients with relapsed/refractory DLBCL or HL who received GDP as salvage therapy between September 2002 and June 2010. We identified 235 patients: 152 DLBCL, 83 HL. Overall response rates were 49% and 71% for patients with DLBCL and HL, respectively. Within the transplant-eligible population, 52% of patients with DLBCL and 96% of patients with HL proceeded to stem cell transplantation. The 2-year progression-free survival and overall survival were 21% and 28% in the DLBCL cohort, and 58% and 85% in the HL group. GDP is an effective and well-tolerated out-patient salvage regimen for relapsed/refractory DLBCL and HL.
authors.affiliation: a Centre for Lymphoid Cancer, British Columbia Cancer Agency, The University of British Columbia , Vancouver , BC , Canada.
authors.forename: Alden A
authors.initials: AA
authors.lastname: Moccia
authors.affiliation: a Centre for Lymphoid Cancer, British Columbia Cancer Agency, The University of British Columbia , Vancouver , BC , Canada.
authors.forename: Felicitas
authors.initials: F
authors.lastname: Hitz
authors.affiliation: a Centre for Lymphoid Cancer, British Columbia Cancer Agency, The University of British Columbia , Vancouver , BC , Canada.
authors.forename: Paul
authors.initials: P
authors.lastname: Hoskins
authors.affiliation: a Centre for Lymphoid Cancer, British Columbia Cancer Agency, The University of British Columbia , Vancouver , BC , Canada.
authors.forename: Richard
authors.initials: R
authors.lastname: Klasa
authors.affiliation: b Leukemia/Bone Marrow Transplantation Program, British Columbia Cancer Agency , The University of British Columbia , Vancouver , BC , Canada.
authors.forename: Maryse M
authors.initials: MM
authors.lastname: Power
authors.affiliation: a Centre for Lymphoid Cancer, British Columbia Cancer Agency, The University of British Columbia , Vancouver , BC , Canada.
authors.forename: Kerry J
authors.initials: KJ
authors.lastname: Savage
authors.affiliation: a Centre for Lymphoid Cancer, British Columbia Cancer Agency, The University of British Columbia , Vancouver , BC , Canada.
authors.forename: Tamara
authors.initials: T
authors.lastname: Shenkier
authors.affiliation: b Leukemia/Bone Marrow Transplantation Program, British Columbia Cancer Agency , The University of British Columbia , Vancouver , BC , Canada.
authors.forename: John D
authors.initials: JD
authors.lastname: Shepherd
authors.affiliation: c Department of Pathology, British Columbia Cancer Agency , The University of British Columbia , Vancouver , BC , Canada.
authors.forename: Graham W
authors.initials: GW
authors.lastname: Slack
authors.affiliation: b Leukemia/Bone Marrow Transplantation Program, British Columbia Cancer Agency , The University of British Columbia , Vancouver , BC , Canada.
authors.forename: Kevin W
authors.initials: KW
authors.lastname: Song
authors.affiliation: c Department of Pathology, British Columbia Cancer Agency , The University of British Columbia , Vancouver , BC , Canada.
authors.forename: Randy D
authors.initials: RD
authors.lastname: Gascoyne
authors.affiliation: a Centre for Lymphoid Cancer, British Columbia Cancer Agency, The University of British Columbia , Vancouver , BC , Canada.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Connors
authors.affiliation: a Centre for Lymphoid Cancer, British Columbia Cancer Agency, The University of British Columbia , Vancouver , BC , Canada.
authors.forename: Laurie H
authors.initials: LH
authors.lastname: Sehn
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin; D003841:Deoxycytidine / Q000031:analogs & derivatives; D003907:Dexamethasone; D019008:Drug Resistance, Neoplasm; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012008:Recurrence; D019233:Retreatment; D012189:Retrospective Studies; D016879:Salvage Therapy; D016896:Treatment Outcome; D055815:Young Adult; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D003907:Dexamethasone; D002945:Cisplatin; D000093542:Gemcitabine
keywords: Chemotherapy; DLBCL; GDP; Hodgkin; gemcitabine; lymphoma; salvage